Neonatal Fc Receptor Blockers [MoA] - N0000194005

Pharmacologic Class Information

Pharmacologic Code N0000194005
Pharmacologic Name Neonatal Fc Receptor Blockers
Pharmacologic Uses
  • neonatal Fc receptor blocker
Pharmacologic Concept Mechanisms of Action - [MoA]
Pharmacologic Concept Description This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

NDC Products with Neonatal Fc Receptor Blockers

The table contains 6 products whose active ingredient are classified under the same pharmacologic class Neonatal Fc Receptor Blockers [MoA].

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
50474-980Rystiggo Non-Proprietary Name: RozanolixizumabInjection, SolutionSubcutaneousUcb, Inc.ACTIVE
50474-981Rystiggo Non-Proprietary Name: RozanolixizumabInjection, SolutionSubcutaneousUcb, Inc.ACTIVE
50474-982Rystiggo Non-Proprietary Name: RozanolixizumabInjection, SolutionSubcutaneousUcb, Inc.ACTIVE
50474-983Rystiggo Non-Proprietary Name: RozanolixizumabInjection, SolutionSubcutaneousUcb, Inc.ACTIVE
73475-3041Vyvgart Non-Proprietary Name: Efgartigimod AlfaInjectionIntravenousArgenx UsACTIVE
73475-3102Vyvgart Hytrulo Non-Proprietary Name: Efgartigimod Alfa And Hyaluronidase (human Recombinant)Injection, SolutionSubcutaneousArgenx UsACTIVE